AR055602A1 - A PHARMACEUTICAL COMPOSITION OF MICROPARTICLES OF 7-TERBUTOXI-IMINO-METIL-CAMPTOTECINA - Google Patents

A PHARMACEUTICAL COMPOSITION OF MICROPARTICLES OF 7-TERBUTOXI-IMINO-METIL-CAMPTOTECINA

Info

Publication number
AR055602A1
AR055602A1 ARP060103450A ARP060103450A AR055602A1 AR 055602 A1 AR055602 A1 AR 055602A1 AR P060103450 A ARP060103450 A AR P060103450A AR P060103450 A ARP060103450 A AR P060103450A AR 055602 A1 AR055602 A1 AR 055602A1
Authority
AR
Argentina
Prior art keywords
microparticles
imino
terbutoxi
camptotecina
metil
Prior art date
Application number
ARP060103450A
Other languages
Spanish (es)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37056484&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR055602(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR055602A1 publication Critical patent/AR055602A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

La presente se refiere a composiciones farmacéuticas en micropartículas, en donde el agente activo es un inhibidor de topoisomerasa I, en particular 7-terbutoxi-imino-metil-camptotecina, que es util para el tratamiento y la prevencion de enfermedades proliferativas, incluyendo cáncer.This refers to pharmaceutical compositions in microparticles, wherein the active agent is a topoisomerase I inhibitor, in particular 7-terbutoxy-imino-methyl-camptothecin, which is useful for the treatment and prevention of proliferative diseases, including cancer.

ARP060103450A 2005-08-10 2006-08-08 A PHARMACEUTICAL COMPOSITION OF MICROPARTICLES OF 7-TERBUTOXI-IMINO-METIL-CAMPTOTECINA AR055602A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70713905P 2005-08-10 2005-08-10

Publications (1)

Publication Number Publication Date
AR055602A1 true AR055602A1 (en) 2007-08-29

Family

ID=37056484

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103450A AR055602A1 (en) 2005-08-10 2006-08-08 A PHARMACEUTICAL COMPOSITION OF MICROPARTICLES OF 7-TERBUTOXI-IMINO-METIL-CAMPTOTECINA

Country Status (20)

Country Link
EP (1) EP1915132A1 (en)
JP (1) JP2009504616A (en)
KR (1) KR20080034989A (en)
CN (1) CN101287448A (en)
AR (1) AR055602A1 (en)
AU (1) AU2006277879A1 (en)
BR (1) BRPI0614757A2 (en)
CA (1) CA2618084A1 (en)
EC (1) ECSP088166A (en)
GT (1) GT200600364A (en)
IL (1) IL189076A0 (en)
MA (1) MA29735B1 (en)
MX (1) MX2008001965A (en)
NO (1) NO20081213L (en)
PE (1) PE20070232A1 (en)
RU (1) RU2008108885A (en)
TN (1) TNSN08062A1 (en)
TW (1) TW200800195A (en)
WO (1) WO2007017514A1 (en)
ZA (1) ZA200800726B (en)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5726181A (en) * 1995-06-05 1998-03-10 Bionumerik Pharmaceuticals, Inc. Formulations and compositions of poorly water soluble camptothecin derivatives
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
IT1306129B1 (en) * 1999-04-13 2001-05-30 Sigma Tau Ind Farmaceuti ESTERS OF L-CARNITINE OR ALCANOYL L-CARNITINE USABLE CATIONIC COMELIPIDS FOR INTRACELLULAR PLACING OF COMPOUNDS
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
GT200500310A (en) * 2004-11-19 2006-06-19 ORGANIC COMPOUNDS

Also Published As

Publication number Publication date
ECSP088166A (en) 2008-03-26
TNSN08062A1 (en) 2009-07-14
MA29735B1 (en) 2008-09-01
ZA200800726B (en) 2009-08-26
NO20081213L (en) 2008-05-13
RU2008108885A (en) 2009-09-20
BRPI0614757A2 (en) 2011-04-12
GT200600364A (en) 2007-03-19
AU2006277879A1 (en) 2007-02-15
PE20070232A1 (en) 2007-04-09
WO2007017514A1 (en) 2007-02-15
EP1915132A1 (en) 2008-04-30
CN101287448A (en) 2008-10-15
CA2618084A1 (en) 2007-02-15
JP2009504616A (en) 2009-02-05
MX2008001965A (en) 2008-03-26
KR20080034989A (en) 2008-04-22
TW200800195A (en) 2008-01-01
IL189076A0 (en) 2008-08-07

Similar Documents

Publication Publication Date Title
BRPI0809164B8 (en) COMPOSITION FOR TOPICAL ADMINISTRATION AND PHARMACEUTICAL COMPOSITION COMPRISING SAID COMPOSITION
GT200700034A (en) PHARMACEUTICAL COMPOSITIONS OF ANTI-BODY ANTAGONISTS ANTI-CD40
ECSP088904A (en) ARILIMIDAZOLONAS AND ARILTRIAZOLONAS REPLACED AS INHIBITORS OF VASOPRESINE RECEPTORS
CR11299A (en) USEFUL HETEROCICLIC AMIDES FOR THE TREATMENT OF CANCER AND PSORIASIS
CL2008001633A1 (en) Compounds derived from pyrrolidin-3-carboxamide; pharmaceutical composition; and use as erk inhibitors for the treatment of cancer.
CR10748A (en) INDOL COMPOUND
CO6300964A2 (en) A PHARMACEUTICAL COMPOSITION THAT INCLUDES A COMBINATION OF A CHEMOTHERAPEUTIC AGENT AND AN ANTIGLIPICAN ANTIBODY 3
CR11684A (en) REPLACED DIHYDROPIRAZOLONES OF HIF-PROPIL-4- AS HYDROXYLASE INHIBITORS
CR9427A (en) THERAPEUTIC COMBINATION IN CASES OF BENIGN PROSTATIC HYPERPLASIA
ECSP077296A (en) SUBSTITUTED PHENYLAMINOTIAZOLS AND ITS USE
CU24349B1 (en) COMPOSITIONS INCLUDING 2,3-DIHYDROIMIDAZO [1,2-C] SUBSTITUTED KINAZOLINS USEFUL FOR TREATMENT OF CANCER
CL2011002595A1 (en) Use of a combination of an anticancer agent and an antioxidant to treat cancer; and pharmaceutical composition comprising said combination.
DOP2007000043A (en) SUBSTITUTED CHROMANOL DERIVATIVES AND THEIR USE
BRPI0518448A2 (en) pharmaceutical compositions comprising a camptothecin derivative
CL2007003587A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED PYRIMIDINS; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS AND ANOTHER ACTIVE AGENT; AND ITS USE TO TREAT OR PREVENT INFECTION OF HEPATITIS C.
BRPI1015539A2 (en) burn treatment compositions and methods
AR052322A1 (en) N-BENZOIL-ESTAUROSPORINE COMPOUNDS, PROCESSES FOR PREPARATION AND PHARMACEUTICAL COMPOSITION
PE20150773A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE SUSTAINED RELEASE OF PHENYLEPHRINE
UY33530A (en) PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF RESPIRATORY AND INFLAMMATORY DISEASES
UY30675A1 (en) METHODS FOR THE TREATMENT OF DEPRESSION
ES2723778T3 (en) Therapy directed at cancer stem cells and against drug-resistant cancer
CO6280474A2 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF EFFECTIVE EJACULATION
CL2011000614A1 (en) Solid oral dosage form comprising alisquirene alone or in combination with another active agent; Preparation process; and use in the treatment of diseases such as hypertension, angina, atherosclerosis, among others.
AR055602A1 (en) A PHARMACEUTICAL COMPOSITION OF MICROPARTICLES OF 7-TERBUTOXI-IMINO-METIL-CAMPTOTECINA
ECSP12012332A (en) ASSOCIATION OF INHIBITORS OF XANTINA OXIDASE AND THE INSTATINE AND ITS USE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal